Search Results

Talaris Therapeutics, Inc. (Nasdaq: TALS) (“Talaris”) today announced the results of the special meeting of its stockholders held on October 17, 2023.

Talaris Therapeutics, Inc. (Nasdaq: TALS) (“Talaris”) and Tourmaline Bio, Inc. (“Tourmaline”), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune diseases, today announced that the companies have entered into a definitive agreement under which Tourmaline will combine with Talaris in an all-stock transaction (the “Merger”).

Talaris Therapeutics, Inc. announced that its Board of Directors has declared a special dividend in connection with the previously announced merger with Tourmaline Bio, Inc. pursuant to the Agreement and Plan of Merger, dated June 22, 2023.

New York Blood Center Enterprises and Talaris Therapeutics, Inc. announced NYBCe’s acquisition of commercial-scale cell and gene therapy development and manufacturing facilities, as well as certain technologies and equipment from Talaris in Houston, Texas and Louisville, Kentucky.

Tourmaline Bio, Inc., a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune diseases, announced the completion of its previously announced merger with Talaris Therapeutics, Inc.

Talaris Therapeutics, Inc., announced that it has completed a review of its business and program prospects.

Talaris Therapeutics, Inc. today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at the 2022 Cell & Gene Meeting on the Mesa being held October 11-13, 2022 in Carlsbad, California.

Talaris Therapeutics, Inc. today announced that Scott Requadt, Chief Executive Officer of Talaris, will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference being held virtually on Tuesday, November 29, 2022 at 4:20 PM ET.

Talaris Therapeutics is cutting one-third of its workforce and dropping two clinical trials studying its lead candidate.